Daxor's blood volume analyzer (bva-100®) to be used as a key metric in study of “long hauler” covid-19 patients

Oak ridge, tn, may 25, 2022 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, announces today participation in the national institutes of health (nih) intramural research program-sponsored study titled “an observational study of neurologic function after covid-19 infection” utilizing daxor's bva-100 (blood volume analyzer, “bva”) technology. the study is being conducted under the leadership of avindra nath, m.d. at the national institute of neurological disorders and stroke (ninds) located in bethesda, maryland.
DXR Ratings Summary
DXR Quant Ranking